艾司奥美拉唑和伊托必利联合瑞巴派特胶囊治疗反流性食管炎的疗效及安全性

Efficacy and safety of esomeprazole,itopride combined with rebapide capsule in the treatment of reflux esophagitis

目的探讨艾司奥美拉唑、伊托必利联合瑞巴派特胶囊治疗反流性食管炎的临床效果。方法选取2021年6月至2022年2月于新疆维吾尔自治区人民医院确诊为反流性食管炎的84例患者作为研究对象,采用随机数字表法分为对照组与观察组,每组42例。对照组给予艾司奥美拉唑、伊托必利治疗,观察组在此基础上联合瑞巴派特胶囊治疗。比较两组临床疗效、症状评分、胃食管反流病问卷评分(GERDQ)评分、反流性疾病问卷评分(RDQ)、胃食管反流病健康相关生命质量评分(GERD-HRQL)及不良反应发生情况。结果观察组治疗总有效率为95.2%,高于对照组的78.6%,差异有统计学意义(P<0.05)。治疗后,观察组反酸、胸骨后疼痛症状评分低于对照组,差异有统计学意义(P<0.05);两组烧心症状评分比较差异无统计学意义。治疗后,观察组GERDQ、RDQ、GERD-HRQL评分均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论艾司奥美拉唑、伊托必利联合瑞巴派特胶囊治疗反流性食管炎安全且疗效更佳,值得临床推广应用。

Objective To explore the clinical effect of esomeprazole,itopride combined with rebapide capsule in the treatment of reflux esophagitis.Methods 84 patients with reflux esophagitis diagnosed in People's Hospital of Xinjiang Uygur Autonomous Region from June 2021 to February 2022 were selected as the research subjects,and they were divided into the control group and the observation group according to random number table method,with 42 cases in each group.The control group was treated with esomeprazole and itopride,and the observation group was treated with rebamipide capsule on the basis of control group.The clinical efficacy,symptom score,the gastroesophageal reflux disease questionnaire(GERDQ)score,reflux disease questionnaire(RDQ)score,gastroesophageal reflux diseas-health-related quality of life(GERD-HRQL)score and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.2%,which was higher than 78.6%in the control group,and the difference was statistically significant(P<0.05).After treatment,the score of acid reflux,substernal pain symptoms in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05);there was no significant difference in the scores of heartburn symptoms between the two groups.After treatment,the scores of GERDQ,RDQ and GERDHRQL in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Esomeprazole,itopride combined with rebapide capsule in the treatment of reflux esophagitis is safe and has better efficacy,which is worthy of clinical promotion and application.